Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Study protocol

The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population

Authors: Edmund J Lamb, Elizabeth A Brettell, Paul Cockwell, Neil Dalton, Jon J Deeks, Kevin Harris, Tracy Higgins, Philip A Kalra, Kamlesh Khunti, Fiona Loud, Ryan S Ottridge, Claire C Sharpe, Alice J Sitch, Paul E Stevens, Andrew J Sutton, Maarten W Taal

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Uncertainty exists regarding the optimal method to estimate glomerular filtration rate (GFR) for disease detection and monitoring. Widely used GFR estimates have not been validated in British ethnic minority populations.

Methods/design

Iohexol measured GFR will be the reference against which each estimating equation will be compared. The estimating equations will be based upon serum creatinine and/or cystatin C. The eGFR-C study has 5 components:
1) A prospective longitudinal cohort study of 1300 adults with stage 3 chronic kidney disease followed for 3 years with reference (measured) GFR and test (estimated GFR [eGFR] and urinary albumin-to-creatinine ratio) measurements at baseline and 3 years. Test measurements will also be undertaken every 6 months. The study population will include a representative sample of South-Asians and African-Caribbeans. People with diabetes and proteinuria (ACR ≥30 mg/mmol) will comprise 20-30% of the study cohort.
2) A sub-study of patterns of disease progression of 375 people (125 each of Caucasian, Asian and African-Caribbean origin; in each case containing subjects at high and low risk of renal progression). Additional reference GFR measurements will be undertaken after 1 and 2 years to enable a model of disease progression and error to be built.
3) A biological variability study to establish reference change values for reference and test measures.
4) A modelling study of the performance of monitoring strategies on detecting progression, utilising estimates of accuracy, patterns of disease progression and estimates of measurement error from studies 1), 2) and 3).
5) A comprehensive cost database for each diagnostic approach will be developed to enable cost-effectiveness modelling of the optimal strategy.
The performance of the estimating equations will be evaluated by assessing bias, precision and accuracy. Data will be modelled as a linear function of time utilising all available (maximum 7) time points compared with the difference between baseline and final reference values. The percentage of participants demonstrating large error with the respective estimating equations will be compared. Predictive value of GFR estimates and albumin-to-creatinine ratio will be compared amongst subjects that do or do not show progressive kidney function decline.

Discussion

The eGFR-C study will provide evidence to inform the optimal GFR estimate to be used in clinical practice.

Trial registration

ISRCTN42955626.
Appendix
Available only for authorised users
Literature
1.
Carter JL, Stevens PE, Irving JE, Lamb EJ: Estimating glomerular filtration rate: comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular emphasis on the effect of age. QJM. 2011, 104 (10): 839-847. 10.1093/qjmed/hcr077.CrossRefPubMed
2.
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003, 41 (1): 1-12.CrossRefPubMed
3.
Stevens PE, O’Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK: Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007, 72 (1): 92-99. 10.1038/sj.ki.5002273.CrossRefPubMed
4.
5.
Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol. 1995, 6 (2): 257-263.PubMed
6.
National Institute for Health and Care Excellence: Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. Clinical Guideline. 2008, 73: Available from http://​www.​nice.​org.​uk/​Guidance/​CG73.
7.
de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2011, 117 (3): c213-224. 10.1159/000320341.CrossRefPubMed
8.
Moynihan R, Doust J, Henry D: Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012, 344: e3502-10.1136/bmj.e3502.CrossRefPubMed
9.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130 (6): 461-470. 10.7326/0003-4819-130-6-199903160-00002.CrossRefPubMed
10.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009, 150 (9): 604-612. 10.7326/0003-4819-150-9-200905050-00006.CrossRefPubMedPubMedCentral
11.
Hsu CY, Bansal N: Measured GFR as “gold standard”–all that glitters is not gold?. Clin J Am Soc Nephrol. 2011, 6 (8): 1813-1814. 10.2215/CJN.06040611.CrossRefPubMed
12.
Brochner-Mortensen J, Rodbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest. 1976, 36 (1): 35-43. 10.3109/00365517609068016.CrossRefPubMed
13.
Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M, Remuzzi G: Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol. 1998, 9 (2): 310-313.PubMed
14.
Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM, et al: Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1993, 4 (5): 1159-1171.PubMedPubMedCentral
15.
Wilkinson J, Fleming JS, Waller DG: Effect of food and activity on the reproducibility of isotopic GFR estimation. Nucl Med Commun. 1990, 11 (10): 697-700. 10.1097/00006231-199010000-00005.CrossRefPubMed
16.
Blake GM, Roe D, Lazarus CR: Long-term precision of glomerular filtration rate measurements using 51Cr-EDTA plasma clearance. Nucl Med Commun. 1997, 18 (8): 776-784. 10.1097/00006231-199708000-00012.CrossRefPubMed
17.
Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG: Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1990, 16 (3): 224-235.CrossRefPubMed
18.
Kwong YT, Stevens LA, Selvin E, Zhang YL, Greene T, Van Lente F, Levey AS, Coresh J: Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis. 2010, 56 (1): 39-49. 10.1053/j.ajkd.2010.02.347.CrossRefPubMedPubMedCentral
19.
Fraser CG, Harris EK: Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989, 27 (5): 409-437. 10.3109/10408368909106595.CrossRefPubMed
20.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006, 145 (4): 247-254. 10.7326/0003-4819-145-4-200608150-00004.CrossRefPubMed
21.
Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000, 11 (suppl): 155A-
22.
Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, et al: Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006, 52 (1): 5-18. 10.1373/clinchem.2005.0525144.CrossRefPubMed
23.
Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K: Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012, 156: 785-795. 10.7326/0003-4819-156-11-201203200-00391.CrossRefPubMed
24.
Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002, 40 (2): 221-226. 10.1053/ajkd.2002.34487.CrossRefPubMed
25.
Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem. 2002, 48 (5): 699-707.PubMed
26.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al: A new equation to estimate glomerular filtration rate from standardized creatinine and cystatin C. N Engl J Med. 2012, 367 (1): 20-29. 10.1056/NEJMoa1114248.CrossRefPubMedPubMedCentral
27.
Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, Farmer CK, Irving J, O’Riordan SE, Dalton RN, et al: Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis. 2013, 61 (1): 57-66. 10.1053/j.ajkd.2012.06.016.CrossRefPubMed
28.
Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, Schuchardt M, Tolle M, Ziebig R, et al: Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012, 157 (7): 471-481. 10.7326/0003-4819-157-7-201210020-00003.CrossRefPubMed
29.
Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O’Connor D, Ojo A, Phillips R, Sika M, Wright J: Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis. 2001, 38 (4): 744-753. 10.1053/ajkd.2001.27691.CrossRefPubMed
30.
Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, et al: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006, 17 (10): 2937-2944. 10.1681/ASN.2006040368.CrossRefPubMed
31.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009, 53 (6): 982-992. 10.1053/j.ajkd.2008.12.034.CrossRefPubMed
32.
Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S: Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010, 56 (1): 32-38. 10.1053/j.ajkd.2010.02.344.CrossRefPubMed
33.
Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, et al: Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010, 56 (3): 486-495. 10.1053/j.ajkd.2010.03.026.CrossRefPubMedPubMedCentral
34.
Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, Sethi S, Lee EJ: GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011, 58 (1): 56-63. 10.1053/j.ajkd.2011.02.393.CrossRefPubMed
35.
Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin P, Susantitaphong P, Trakarnvanich T, Kanjanabuch T, Avihingsanon Y, Tungsanga K, et al: The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant. 2011, 26 (9): 2780-2785. 10.1093/ndt/gfq815.CrossRefPubMed
36.
Flamant M, Vidal-Petiot E, Metzger M, Haymann JP, Letavernier E, Delatour V, Karras A, Thervet E, Boffa JJ, Houillier P, et al: Performance of GFR estimating equations in African Europeans: basis for a lower race-ethnicity factor than in African Americans. Am J Kidney Dis. 2013, 62 (1): 182-184.CrossRefPubMed
37.
Madala ND, Nkwanyana N, Dubula T, Naiker IP: Predictive performance of eGFR equations in South Africans of African and Indian ancestry compared with 99mTc-DTPA imaging. Int Urol Nephrol. 2012, 44 (3): 847-855. 10.1007/s11255-011-9928-7.CrossRefPubMed
38.
Kidney Disease Improving Global Outcomes: Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013, 3 (Suppl): 1-150.
39.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004, 164 (6): 659-663. 10.1001/archinte.164.6.659.CrossRefPubMed
40.
Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF: Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006, 69 (12): 2155-2161. 10.1038/sj.ki.5000270.CrossRefPubMed
41.
Ruggenenti P, Perna A, Remuzzi G: ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001, 12 (12): 2832-2837.PubMed
42.
Gall MA, Nielsen FS, Smidt UM, Parving HH: The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993, 36 (10): 1071-1078. 10.1007/BF02374501.CrossRefPubMed
43.
MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004, 27 (1): 195-200. 10.2337/diacare.27.1.195.CrossRefPubMed
44.
Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed). 1987, 294 (6585): 1443-1447. 10.1136/bmj.294.6585.1443.CrossRef
45.
Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed). 1986, 293 (6545): 471-474. 10.1136/bmj.293.6545.471.CrossRef
46.
Hoefield RA, Kalra PA, Baker PG, Sousa I, Diggle PJ, Gibson MJ, O’Donoghue DJ, Middleton RJ, New JP: The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant. 2011, 26 (3): 887-892. 10.1093/ndt/gfq526.CrossRefPubMed
47.
Gowans EM, Fraser CG: Biological variation of serum and urine creatinine and creatinine clearance: ramifications for interpretation of results and patient care. Ann Clin Biochem. 1988, 25: 259-263.CrossRefPubMed
48.
Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW: Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem. 1998, 44 (7): 1535-1539.PubMed
49.
Reinhard M, Erlandsen EJ, Randers E: Biological variation of cystatin C and creatinine. Scand J Clin Lab Invest. 2009, 69 (8): 831-836. 10.3109/00365510903307947.CrossRefPubMed
50.
Delanaye P, Cavalier E, Depas G, Chapelle JP, Krzesinski JM: New data on the intraindividual variation of cystatin C. Nephron Clin Pract. 2008, 108 (4): c246-248. 10.1159/000124327.CrossRefPubMed
51.
Andersen TB, Erlandsen EJ, Frokiaer J, Eskild-Jensen A, Brochner-Mortensen J: Comparison of within- and between-subject variation of serum cystatin C and serum creatinine in children aged 2–13 years. Scand J Clin Lab Invest. 2010, 70 (1): 54-59. 10.3109/00365510903556308.CrossRefPubMed
52.
Bandaranayake N, Ankrah-Tetteh T, Wijeratne S, Swaminathan R: Intra-individual variation in creatinine and cystatin C. Clin Chem Lab Med. 2007, 45 (9): 1237-1239.CrossRefPubMed
53.
Toffaletti JG, McDonnell EH: Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function. Clin Chim Acta. 2008, 395 (1–2): 115-119.CrossRefPubMed
54.
Padala S, Tighiouart H, Inker LA, Contreras G, Beck GJ, Lewis J, Steffes M, Rodby RA, Schmid CH, Levey AS: Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis. 2012, 60 (2): 217-224. 10.1053/j.ajkd.2012.01.024.CrossRefPubMedPubMedCentral
55.
Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, Safford MM, Zhang X, Muntner P, Warnock D: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011, 305 (15): 1545-1552. 10.1001/jama.2011.468.CrossRefPubMedPubMedCentral
56.
57.
Turin TC, Tonelli M, Manns BJ, Ravani P, Ahmed SB, Hemmelgarn BR: Chronic kidney disease and life expectancy. Nephrol Dial Transplant. 2012, 27 (8): 3182-3186. 10.1093/ndt/gfs052.CrossRefPubMed
58.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8 (4): R204-212. 10.1186/cc2872.CrossRefPubMedPubMedCentral
59.
Greenberg N, Roberts WL, Bachmann LM, Wright EC, Dalton RN, Zakowski JJ, Greg Miller W: Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and jaffe method principles. Clin Chem. 2012, 58 (2): 391-401. 10.1373/clinchem.2011.172288.CrossRefPubMed
60.
Brochner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest. 1972, 30 (3): 271-274. 10.3109/00365517209084290.CrossRefPubMed
61.
Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I: First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med. 2010, 48 (11): 1619-1621.CrossRefPubMed
62.
O’Brien TE, Funk GM: A gentle introduction to optimal design for regression models. The American Statistician. 2003, 57 (4): 265-267. 10.1198/0003130032378.CrossRef
63.
Department of Health: National Service Framework for Renal Services. Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care. 2005
64.
Levin A, Stevens PE: Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol. 2011, 7 (8): 446-457. 10.1038/nrneph.2011.86.CrossRefPubMed
65.
Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, Dietz K, Risler T: Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med. 2001, 29 (8): 1544-1550. 10.1097/00003246-200108000-00008.CrossRefPubMed
66.
Schwartz GJ, Work DF: Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009, 4 (11): 1832-1843. 10.2215/CJN.01640309.CrossRefPubMed
Metadata
Title
The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population
Authors
Edmund J Lamb
Elizabeth A Brettell
Paul Cockwell
Neil Dalton
Jon J Deeks
Kevin Harris
Tracy Higgins
Philip A Kalra
Kamlesh Khunti
Fiona Loud
Ryan S Ottridge
Claire C Sharpe
Alice J Sitch
Paul E Stevens
Andrew J Sutton
Maarten W Taal
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-13

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue

Research article

Shorter daily dwelling time in peritoneal dialysis attenuates the epithelial-to-mesenchymal transition of mesothelial cells

Research article

Non-inferiority of creatinine excretion rate to urinary L-FABP and NGAL as predictors of early renal allograft function

Research article

Injurious mechanical ventilation causes kidney apoptosis and dysfunction during sepsis but not after intra-tracheal acid instillation: an experimental study

Research article

Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial

Research article

Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients

Research article

The incidence and risk factors of acute kidney injury after hepatobiliary surgery: a prospective observational study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits